- Home
- NCMI vs SNY Comparison
NCMI vs SNY Comparison
Compare NCMI & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCMI
- SNY
- Stock Information
- Founded
- NCMI 2005
- SNY 1994
- Country
- NCMI United States
- SNY France
- Employees
- NCMI 254
- SNY N/A
- Industry
- NCMI Advertising
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- NCMI Consumer Discretionary
- SNY Health Care
- Exchange
- NCMI Nasdaq
- SNY Nasdaq
- Market Cap
- NCMI 444.2M
- SNY 116.5B
- IPO Year
- NCMI 2007
- SNY N/A
- Fundamental
- Price
- NCMI $4.89
- SNY $48.61
- Analyst Decision
- NCMI Strong Buy
- SNY Buy
- Analyst Count
- NCMI 5
- SNY 2
- Target Price
- NCMI $7.40
- SNY $62.50
- AVG Volume (30 Days)
- NCMI 633.9K
- SNY 2.2M
- Earning Date
- NCMI 08-04-2025
- SNY 07-31-2025
- Dividend Yield
- NCMI 2.52%
- SNY 3.29%
- EPS Growth
- NCMI N/A
- SNY 39.56
- EPS
- NCMI N/A
- SNY 5.45
- Revenue
- NCMI $238,300,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- NCMI $8.56
- SNY $3.39
- Revenue Next Year
- NCMI $12.67
- SNY $7.05
- P/E Ratio
- NCMI N/A
- SNY $17.37
- Revenue Growth
- NCMI 42.10
- SNY N/A
- 52 Week Low
- NCMI $4.12
- SNY $45.80
- 52 Week High
- NCMI $7.60
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- NCMI 39.74
- SNY 46.26
- Support Level
- NCMI $4.57
- SNY $47.99
- Resistance Level
- NCMI $4.84
- SNY $49.43
- Average True Range (ATR)
- NCMI 0.16
- SNY 0.58
- MACD
- NCMI -0.02
- SNY 0.18
- Stochastic Oscillator
- NCMI 24.36
- SNY 56.15
About NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.